From the Department of Anaesthesiology, Ganzhou People's Hospital, Jiangxi, Ganzhou, China (T-YH, R-PZ, W-BZ, G-MH, X-CL).
Eur J Anaesthesiol. 2024 Dec 1;41(12):898-909. doi: 10.1097/EJA.0000000000002057. Epub 2024 Sep 11.
Hypotension is common during anaesthesia. Increasing number of studies have reported that remimazolam may be associated with lower incidence of intra-operative hypotension compared with other anaesthetics. However, the results remain controversial.
This study aimed to evaluate the influence of remimazolam on intra-operative hypotension and its related outcomes (hypoxaemia, bradycardia and time to awake).
A systematic review of randomised controlled trials (RCTs) with meta-analyses.
PubMed, Cocharane and Embase databases were searched to identify eligible RCTs published up to June 2024.
RCTs published in English were eligible for inclusion. The study patients were 18 years or older who were administered with remimazolam and other positive control agents in either the pre-operative or intra-operative period. The incidence of intra-operative hypotension was identified in these studies.
This study evaluated 34 trials including 4847 individuals. Basing on moderate-certainty evidence, we found that remimazolam administration reduced the incidence of intra-operative hypotension [risk ratio (RR) = 0.48, 95% confidence interval (95% CI): 0.41 to 0.57] and bradycardia (16 studies, n = 2869, RR = 0.40, 95% CI: 0.29 to 0.54). No difference was observed in the incidence of hypoxaemia (RR = 0.70, 95% CI: 0.48 to 1.01) and time to awake (MD = -0.91, 95% CI: -2.42 to 0.60). The remarkable association between remimazolam and hypotension remained robust and significant, regardless of general anaesthesia or procedural sedation ( P < 0.01, I2 = 82%). No significant difference was found between different control drugs ( P = 0.97, I2 = 82%).
Moderate-quality evidence shows that remimazolam administration to patients undergoing general anaesthesia or procedural sedation decreases the incidence of intra-operative hypotension and bradycardia.
低血压在麻醉期间很常见。越来越多的研究报告称,与其他麻醉剂相比,瑞马唑仑可能与术中低血压的发生率较低有关。然而,结果仍存在争议。
本研究旨在评估瑞马唑仑对术中低血压及其相关结局(低氧血症、心动过缓以及清醒时间)的影响。
系统评价随机对照试验(RCT)并进行荟萃分析。
检索 PubMed、Cochrane 和 Embase 数据库,以确定截至 2024 年 6 月发表的合格 RCT。
发表于英文期刊的 RCT 符合纳入标准。研究患者为年龄在 18 岁及以上的成年人,在术前或术中接受瑞马唑仑和其他阳性对照药物治疗。这些研究中确定了术中低血压的发生率。
本研究评估了 34 项试验,共纳入 4847 例患者。基于中等确定性证据,我们发现瑞马唑仑给药可降低术中低血压的发生率[风险比(RR)=0.48,95%置信区间(95%CI):0.41 至 0.57]和心动过缓(16 项研究,n=2869,RR=0.40,95%CI:0.29 至 0.54)。低氧血症的发生率无差异(RR=0.70,95%CI:0.48 至 1.01),清醒时间也无差异(MD=-0.91,95%CI:-2.42 至 0.60)。瑞马唑仑与低血压之间的显著关联仍然稳健且具有统计学意义,无论全身麻醉还是程序性镇静(P<0.01,I2=82%)。不同对照药物之间无显著差异(P=0.97,I2=82%)。
中等质量证据表明,在接受全身麻醉或程序性镇静的患者中使用瑞马唑仑可降低术中低血压和心动过缓的发生率。